A phase 2A, randomized, double blind, placebo controlled, dose escalation study to evaluate the safety and effect on exercise challenge testing of multiple fixed subcutaneous doses of MEDI-528. A humanised anti interleukin 9 monoclonal antibody, in adults with stable asthma and exercise induced bronchoconstriction.

Trial Profile

A phase 2A, randomized, double blind, placebo controlled, dose escalation study to evaluate the safety and effect on exercise challenge testing of multiple fixed subcutaneous doses of MEDI-528. A humanised anti interleukin 9 monoclonal antibody, in adults with stable asthma and exercise induced bronchoconstriction.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 May 2014

At a glance

  • Drugs Enokizumab (Primary)
  • Indications Asthma; Bronchoconstriction; Bronchospasm
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 25 Oct 2011 Planned End Date changed from 1 Jun 2009 to 1 Oct 2009 as reported by ClinicalTrials.gov.
    • 14 May 2010 Results from 9 patients presented at 106th International Conference of the American Thoracic Society.
    • 24 Feb 2010 Status changed from suspended to discontinued as reported on ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top